Seer reported third-quarter revenue of $4.0 million versus $3.1 million, but cut full year 2026 revenue guidance to $13.5 million to $14.5 million from $16 to $18 million amid funding constraints and delayed purchases.
SEER · Seer, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Seer reported a 20% revenue decline for the nine months ended September 30, 2026, while net loss narrowed to $47.5 million from $57.6 million. Cash, cash equivalents and investments totaled $198.1 million, while operating cash use was $34.5 million.
Seer reported third-quarter revenue of $4.0 million and cut full-year 2026 revenue guidance to $13.5 million to $14.5 million from $16 million to $18 million, citing funding pressure and delayed opportunities.
Seer, Inc.’s Special Committee unanimously rejected two unsolicited acquisition proposals, concluding a sale would undervalue the company, leaving it as an independent public company. The Radoff-JEC Group proposed $2.55 per share in cash plus a contingent value right.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q3 FY26 earnings call · Nov 10, 2026TL;DR. Revenue increased sequentially to $4.0 million, net loss narrowed, and SEER retained substantial cash and scientific validation of its platform. New pharmaceutical adoption and repeat consumable purchases supported growth, but full-year revenue guidance was reduced to $13.5 million–$14.5 million amid funding-related delays, lower year-over-year revenue, sequential gross-margin pressure, flat consumable pull-through, and negative free cash flow.
- + Third-quarter revenue increased sequentially to $4.0 million from $3.1 million. new
- + Established customers continued buying consumables, while several new large pharmaceutical customers purchased instruments and consumables. new
- + Net loss narrowed to $13.7 million from $18.2 million in the prior-year period. new
- + SEER ended the quarter with approximately $198.1 million in cash, cash equivalents, and investments and believes its capital is sufficient to reach cash flow breakeven. new
- + Publications, preprints, and reviews describing Proteograph research increased to 116 from 95. new
- + SEER will remain an independent public company, and ITC investigative staff recommended granting the full exclusion and cease-and-desist orders requested in its Nanomics investigation. new
- − Full-year 2026 revenue guidance was reduced to $13.5 million–$14.5 million from $16 million–$18 million. new
- − Revenue decreased 3% from the prior-year period, to $4.0 million from $4.1 million. new
- − Gross margin declined 130 basis points sequentially to 47%. new
- − Funding constraints and customer uncertainty over SEER's future extended revenue-conversion timelines, delaying several late-stage opportunities. new
- − Free cash flow was approximately negative $34.8 million for the first nine months of 2026.
- − Consumable pull-through was relatively flat sequentially and purchasing remained project-driven, with gaps between customer reorders. new
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SEER
this stock
Seer, Inc.
|
$87.63M | -14.2% | +17.0% | — | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$136.56B | +18.8% | +46.2% | 34.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$98.84B | +23.8% | +20.8% | 21.1 | 2.1% |
|
MRNA
Moderna, Inc.
|
$90.38B | +657.4% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$66.05B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 10, 2026
- This year
- 47
Seer reported third-quarter revenue of $4.0 million and cut full-year 2026 revenue guidance to $13.5 million to $14.5 million from $16 million to $18 million, citing funding pressure and delayed opportunities.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SEER | -3.7% | -22.7% | -16.0% | -6.6% | -14.2% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | -6.3% | -21.5% | -16.5% | -6.4% | -24.8% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.